Why hormonal health at work is now a legal question, not a wellbeing question

UK employers with 250 or more employees must publish Gender Equality Action Plans from Spring 2027, making hormonal health at work a legal compliance question for the first time. The Employment Rights Act 2025 specifically requires menopause-related actions; government guidance encourages employers to extend to endometriosis, PCOS, fertility, and fibroids. Employers who engage this as a multi-condition obligation, not a single-condition tick-box, arrive at the clinical depth the workforce case actually requires.

_Note: timings reflect the position as of April 2026; secondary regulations are still being finalised and dates may shift._

On 18 December 2025, the Employment Rights Act received Royal Assent. Among its provisions: Gender Equality Action Plans (GEAPs) for UK employers with 250 or more employees. Mandatory publication is currently expected from Spring 2027, with a voluntary phase that opened earlier in 2026. Approximately 10,000 large employers sit within scope, the same population required to publish gender pay gap data. The exact shape and timing of the obligation depends on secondary regulations still being shaped.

The statutory duty under the Act applies specifically to menopause (including perimenopause): employers must publish at least one action that supports affected employees. Government guidance encourages, but does not mandate, extension to other hormonal health conditions including endometriosis, PCOS, fibroids, and fertility. Many employers will choose to extend their action plans voluntarily.

Even though only menopause is statutorily required, the workforce case extends well beyond it. Employers thinking about this as a multi-condition obligation arrive at clinical depth that single-condition responses cannot reach.

The clinical dimension of the obligation

42% of UK employees undergoing fertility treatment report feeling pressure to remain at work throughout, the highest of any country surveyed (Fertility Matters at Work, 2023). Two in five leave or consider leaving their jobs. The CIPD has documented significant gaps in manager training and employer provision across the hormonal health remit. The workforce case for action is established and growing.

The annual cost of inadequate fertility workplace support alone is £217.3 million (Fertility Matters at Work, 2026). Hormonal health absenteeism costs the UK economy approximately £11 billion per year (NHS Confederation / London Economics, 2024). Around 60,000 women are not in employment due to unmanaged menopause (CIPD, 2023). The economic case for action is established and growing.

What the developing standard actually requires

Awareness frameworks and policy templates address the employer's administrative obligations and are a genuine starting point. The developing GEAP direction points toward the clinical layer that sits above awareness: understanding what employees are actually navigating, the intersection of treatment schedules, medication effects, and the psychological burden of conditions that are cyclical, chronic, or both.

Employers building durable responses typically move from policy to practice: from awareness of what employees face to functional understanding that equips managers and commissioners alike. That transition benefits from clinical and occupational health grounding working alongside the HR and DEI functions already in place.

HHEI was founded precisely for this intersection: a CIC whose founding board holds primary care, occupational medicine, and secondary care. Multi-lens by composition, independent by structure, designed to work with the partners already doing this.